Total debt has held near $1.3B after stepping down from $2.7B, and debt-to-equity fell from 84.26 in 2024Q3 to 0.35 in 2026Q3 as equity rebuilt to $3.6B, though the current ratio's decline from 3.13 to 2.48 suggests a narrowing liquidity cushion.
Alnylam Pharmaceuticals, Inc. (ALNY) balance sheet — 24-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 |
|---|
| Total Current Assets | 5.11B | 4.05B | 3.3B | 2.98B | 2.69B | 2.81B | 2.61B | 1.72B | 1.2B | 1.76B | 671.88M | 1.11B | 746.37M | 254.03M | 125.56M | 152.03M | 254.14M | 293.53M | 443.12M | 397.9M | 222.78M | 82.41M | 48.18M | 24.19M | 15.52M |
| Cash & Short-Term Investments | 3.59B | 2.91B | 2.69B | 2.44B | 2.19B | 2.44B | 1.87B | 1.54B | 1.08B | 1.69B | 626.8M | 1.08B | 696.69M | 245.87M | 122.81M | 146.4M | 233.13M | 281.4M | 430.39M | 389.95M | 217.26M | 80M | 46.05M | 23.19M | 15.48M |
| Cash Only | 1.75B | 1.66B | 966.43M | 812.69M | 866.39M | 819.98M | 496.58M | 547.18M | 420.15M | 645.36M | 193.62M | 180.9M | 75.18M | 53.17M | 51.41M | 70.23M | 74.6M | 137.47M | 191.79M | 105.16M | 127.95M | 15.76M | 20.27M | 23.19M | 15.48M |
| Short-Term Investments | 1.83B | 1.25B | 1.73B | 1.63B | 1.33B | 1.62B | 1.38B | 988.98M | 664.01M | 1.05B | 433.18M | 899.64M | 621.51M | 192.7M | 71.41M | 76.17M | 158.53M | 143.93M | 238.6M | 284.79M | 89.31M | 64.25M | 25.77M | 0 | 0 |
| Accounts Receivable | 1.08B | 777.57M | 405.31M | 327.79M | 237.96M | 198.57M | 602.41M | 43.01M | 18.76M | 34M | 23.33M | 8.3M | 39.94M | 4.25M | 104K | 1.47M | 3.45M | 6.04M | 4.19M | 5.03M | 3.83M | 755K | 1.17M | 0 | 0 |
| Days Sales Outstanding | 66.6 | 76.42 | 65.8 | 65.44 | 83.72 | 85.85 | 446.14 | 71.44 | 91.41 | 138.03 | 180.6 | 73.7 | 288.31 | 32.87 | 0.57 | 6.47 | 12.59 | 21.94 | 15.9 | 36.08 | 51.9 | 48.21 | 99.74 | - | - |
| Inventory | 105.91M | 82.72M | 78.51M | 89.15M | 128.96M | 86.36M | 75.2M | 56.35M | 24.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -226.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 29.63 | 44.59 | 88.62 | 104.82 | 278.83 | 224.93 | 351.67 | 820.65 | 4.88K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 281.89M | 116.96M | 126.38M | 132.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.91M | 0 | 0 | 0 | 1.94M | 3.87M | 0 | 0 | 0 | 0 | 373K | 19K |
| Total Non-Current Assets | 2.88B | 915.67M | 944.7M | 847.18M | 854.11M | 834.73M | 792.28M | 679.27M | 374.11M | 229.99M | 590.93M | 281.12M | 333.23M | 166.5M | 161.96M | 129.89M | 139.13M | 187.85M | 111.55M | 95.89M | 17.22M | 15.93M | 17.93M | 10.99M | 592K |
| Property, Plant & Equipment | 792.86M | 708.06M | 693.93M | 725.79M | 738.63M | 733.63M | 706.51M | 646.38M | 320.66M | 181.9M | 114.57M | 27.81M | 21.74M | 16.45M | 19.8M | 14.64M | 18.29M | 18.32M | 19.19M | 13.81M | 12.17M | 10.58M | 11.69M | 4.76M | 526K |
| Fixed Asset Turnover | 6.81x | 5.25x | 3.24x | 2.52x | 1.40x | 1.15x | 0.70x | 0.34x | 0.23x | 0.49x | 0.41x | 1.48x | 2.33x | 2.87x | 3.37x | 5.65x | 5.47x | 5.49x | 5.01x | 3.69x | 2.21x | 0.54x | 0.37x | 0.04x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 275K | 448K | 622K | 795K | 968K | 1.93M | 2.49M | 3.4M | 3.88M | 0 |
| Long-Term Investments | 22.17M | 0 | 0 | 0 | 0 | 0 | 0 | 14.82M | 44.83M | 13.92M | 324.8M | 251.84M | 279.82M | 150.05M | 142.16M | 114.41M | 120.39M | 160.35M | 83.9M | 74.78M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 60.31M | 81.63M | 133.9M | 111.29M | 115.48M | 101.09M | 85.77M | 18.07M | 8.62M | 34.17M | 151.56M | 1.47M | 0 | 0 | 0 | 564K | 0 | 0 | 3.15M | 6.33M | 3.12M | 2.86M | 2.83M | 2.36M | 66K |
| Total Assets | 7.99B | 4.97B | 4.24B | 3.83B | 3.55B | 3.64B | 3.41B | 2.4B | 1.57B | 1.99B | 1.26B | 1.39B | 1.08B | 420.53M | 287.52M | 281.92M | 393.26M | 481.38M | 554.68M | 493.79M | 240.01M | 98.35M | 66.11M | 35.18M | 16.11M |
| Asset Turnover | 0.85x | 0.75x | 0.53x | 0.48x | 0.29x | 0.23x | 0.14x | 0.09x | 0.05x | 0.05x | 0.04x | 0.03x | 0.05x | 0.11x | 0.23x | 0.29x | 0.25x | 0.21x | 0.17x | 0.10x | 0.11x | 0.06x | 0.06x | 0.01x | - |
| Asset Growth % | 125.39% | 17.13% | 10.71% | 7.99% | -2.66% | 6.93% | 42.25% | 52.09% | -21.05% | 57.96% | -8.92% | 28.43% | 156.72% | 46.26% | 1.99% | -28.31% | -18.31% | -13.21% | 12.33% | 105.74% | 144.04% | 48.77% | 87.89% | 118.38% | - |
| Total Current Liabilities | 2.06B | 1.47B | 1.19B | 967.79M | 767.91M | 695.71M | 585.27M | 352.59M | 179.49M | 144.25M | 131.7M | 62.1M | 95.33M | 53.86M | 48.34M | 80.99M | 102.05M | 110.73M | 99.45M | 83.48M | 22.93M | 18.48M | 6.58M | 3.84M | 2.67M |
| Accounts Payable | 135.4M | 115.72M | 88.42M | 55.52M | 98.09M | 73.43M | 51.97M | 49.88M | 59.71M | 28.36M | 54.47M | 16.79M | 15.11M | 5.9M | 4.42M | 5.8M | 9.31M | 12.49M | 2.59M | 3.83M | 4.08M | 1.98M | 910K | 1.51M | 674K |
| Days Payables Outstanding | 38.92 | 62.37 | 99.8 | 65.28 | 212.09 | 191.24 | 243.01 | 726.5 | 12.09K | 774.26 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 361.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.79M | 3.22M | 1.88M | 790K | 558K | 0 |
| Deferred Revenue (Current) | 23.74M | 4.84M | 55.48M | 102.75M | 42.1M | 149.48M | 127.21M | 77.82M | 3.5M | 41.7M | 33.54M | 15.35M | 23.87M | 32.7M | 31.42M | 62.37M | 81.62M | 82.77M | 79.86M | 59.25M | 11.14M | 10.73M | 1M | 333K | 0 |
| Other Current Liabilities | 272.04M | 477.26M | 421.2M | 177.16M | 170.98M | 130.66M | 110.75M | 68.3M | 40.87M | 35.81M | 15.27M | 12.32M | 40.03M | 5.93M | 950K | 484K | 0 | 0 | 1.56M | 1.39M | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 2.48x | 2.76x | 2.78x | 3.08x | 3.51x | 4.04x | 4.47x | 4.87x | 6.69x | 12.23x | 5.10x | 17.80x | 7.83x | 4.72x | 2.60x | 1.88x | 2.49x | 2.65x | 4.46x | 4.77x | 9.72x | 4.46x | 7.33x | 6.29x | 5.81x |
| Quick Ratio | 2.43x | 2.71x | 2.71x | 2.99x | 3.34x | 3.91x | 4.34x | 4.71x | 6.56x | 12.23x | 5.10x | 17.80x | 7.83x | 4.72x | 2.60x | 1.88x | 4.71x | 2.65x | 4.46x | 4.77x | 9.72x | 4.46x | 7.33x | 6.29x | 5.81x |
| Cash Conversion Cycle | 57.31 | 58.63 | 54.62 | 104.98 | 150.46 | 119.54 | 554.8 | 165.58 | -7.13K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.33B | 2.71B | 2.99B | 3.08B | 2.94B | 2.36B | 1.81B | 603.85M | 93.34M | 84.05M | 210.89M | 59.7M | 47.99M | 96.32M | 105.12M | 82.93M | 132.99M | 192.69M | 253.1M | 211.15M | 15.91M | 18.09M | 13.39M | 58.05M | 18.08M |
| Long-Term Debt | 651.09M | 1.01B | 1.02B | 1.02B | 1.02B | 675.7M | 191.28M | 0 | 30M | 30M | 150M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.96M | 5.92M | 5.52M | 6.41M | 1.3M | 0 |
| Capital Lease Obligations | 856.9M | 225.09M | 229.54M | 243.1M | 261.34M | 281.35M | 293.04M | 276.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.47B | 1.48B | 1.73B | 1.63B | 1.46B | 1.25B | 1.1B | 9.33M | 62.88M | 10.97M | 11.5M | 6.73M | 5.01M | 2.92M | 4.25M | 4.44M | 3.01M | 2.8M | 2.98M | 4.12M | 9.99M | 12.57M | 6.98M | 56.74M | 18.08M |
| Total Liabilities | 4.39B | 4.18B | 4.17B | 4.05B | 3.7B | 3.06B | 2.39B | 956.44M | 272.84M | 228.3M | 342.59M | 121.8M | 143.33M | 150.18M | 153.47M | 163.92M | 235.03M | 303.42M | 352.55M | 294.62M | 38.83M | 36.57M | 19.96M | 61.89M | 20.76M |
| Total Debt | 1.26B | 1.28B | 1.3B | 1.31B | 1.32B | 997.59M | 521.19M | 303.82M | 30M | 30M | 150M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.76M | 9.14M | 7.39M | 7.2M | 1.86M | 0 |
| Net Debt | -492.35M | -378.86M | 329.62M | 492.7M | 453.85M | 177.62M | 24.61M | -243.35M | -390.15M | -615.36M | -43.62M | -1.28B | -881.93M | -53.17M | -51.41M | -70.23M | -74.6M | -137.47M | -191.79M | -98.4M | -118.82M | -8.36M | -13.07M | -21.33M | -15.48M |
| Debt / Equity | 0.35x | 1.62x | 19.32x | - | - | 1.70x | 0.51x | 0.21x | 0.02x | 0.02x | 0.16x | - | - | - | - | - | - | - | - | 0.03x | 0.05x | 0.12x | 0.16x | - | - |
| Debt / EBITDA | 1.22x | 2.29x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.48x | -0.68x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 3.27x | 2.28x | -1.66x | -2.58x | -6.23x | -4.96x | -9.13x | - | - | - | - | - | - | - | - | - | - | - | -28.28x | -73.07x | - | - | - | - | - |
| Total Equity | 3.6B | 789.18M | 67.09M | -220.64M | -158.22M | 588.2M | 1.02B | 1.44B | 1.3B | 1.77B | 920.22M | 1.26B | 936.27M | 270.35M | 134.05M | 118M | 158.23M | 177.97M | 202.13M | 199.17M | 201.17M | 61.78M | 46.14M | -26.71M | -4.65M |
| Equity Growth % | 3789.09% | 1076.33% | 130.41% | -39.45% | -126.9% | -42.12% | -29.36% | 10.5% | -26.29% | 91.96% | -27.24% | 35.08% | 246.32% | 101.67% | 13.61% | -25.43% | -11.09% | -11.95% | 1.48% | -1% | 225.63% | 33.89% | 272.77% | -474.84% | - |
| Book Value per Share | 26.11 | 5.86 | 0.53 | -1.77 | -1.30 | 4.97 | 8.84 | 13.17 | 12.94 | 19.51 | 10.75 | 15.06 | 12.60 | 4.39 | 2.67 | 2.78 | 3.76 | 4.27 | 4.92 | 5.15 | 6.31 | 2.81 | 3.88 | -28.33 | -14.02 |
| Total Shareholders' Equity | 3.6B | 789.18M | 67.09M | -220.64M | -158.22M | 588.2M | 1.02B | 1.44B | 1.3B | 1.77B | 920.22M | 1.26B | 936.27M | 270.35M | 134.05M | 118M | 158.23M | 177.97M | 202.13M | 199.17M | 201.17M | 61.78M | 46.14M | -26.71M | -4.65M |
| Common Stock | 1.34M | 1.32M | 1.29M | 1.26M | 1.24M | 1.2M | 1.16M | 1.12M | 1.01M | 997K | 859K | 851K | 772K | 637K | 525K | 427K | 423K | 418K | 414K | 408K | 371K | 267K | 208K | 0 | 0 |
| Retained Earnings | -4.16B | -6.7B | -7.29B | -7.01B | -6.57B | -5.44B | -4.59B | -3.73B | -2.84B | -2.15B | -1.66B | -1.25B | -956.63M | -596.24M | -507.01M | -401M | -343.35M | -299.83M | -252.24M | -225.99M | -140.53M | -105.92M | -63.01M | -29.52M | -4.49M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -44.66M | -20.1M | -34.52M | -23.38M | -44.65M | -33.26M | -43.62M | -36.52M | -33.21M | -34.43M | -33.44M | 4.37M | 48.76M | 19.72M | 15.66M | -165K | 714K | 716K | 1.19M | 300K | 551K | -2.6M | -3.28M | -4.61M | -161K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ALNY stock.
As of 2025, Alnylam Pharmaceuticals, Inc. (ALNY) had total assets of $4.97B including $4.05B in current assets.
Alnylam Pharmaceuticals, Inc. (ALNY) carries total debt of $1.28B, offset by $2.91B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Alnylam Pharmaceuticals, Inc. (ALNY) has total shareholders' equity (book value) of $789.2M ($5.86 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Alnylam Pharmaceuticals, Inc. (ALNY) reported a current ratio of 2.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Leverage and accumulated deficit
Metrics are mathematically derived from official filings.
Equity Rebuilding Despite Persistent Deficit
Based on reported figures, ALNY's equity rose from roughly negative $3M in 2024Q2 to $3.6B in 2026Q3, a shift that reflects retained earnings improvement from a deficit that narrowed from $7.3B to $4.2B over the same period.
The reported equity recovery appears driven primarily by accumulated earnings and capital raised over the period rather than asset growth alone. The accumulated deficit remains very large, which suggests the company is still working through years of losses, and investors should monitor whether earnings quality holds given the earlier analysis of non-operating items inflating net income.
Leverage Falling as Equity Expands
According to reported quarterly figures, ALNY's debt-to-equity ratio compressed from 84.26 in 2024Q3 to 0.35 in 2026Q3, while total debt held steady near $1.3B after an earlier step-down from $2.7B.
The sharp decline in D/E is primarily an equity-denominator effect rather than deleveraging, since absolute debt has been stable at roughly $1.3B since 2025Q4. Debt of this size relative to current cash of $1.8B suggests the company is net cash, but investors should verify the composition of obligations, as financing structures such as royalty-linked liabilities may not be fully captured in headline debt figures.
Cash Cushion Supports Current Liabilities
As reported in financial statements, ALNY held $1.8B in cash in 2026Q3 against a current ratio of 2.48, down from 3.13 in 2026Q1, indicating that short-term obligations are being covered with a narrowing margin of safety.
The current ratio trend suggests current liabilities have grown faster than current assets in recent quarters, which may reflect rising operating payables or deferred obligations tied to commercial expansion. Cash of this magnitude provides a meaningful buffer against near-term shocks, though the falling ratio warrants monitoring as the company scales its commercial and pipeline spending.
Asset-Light Profile With Growing Asset Base
Based on ALNY's reported balance sheet, total assets expanded from $4.0B in 2024Q2 to $8.0B in 2026Q3, while net PP&E grew modestly to $792.9M and goodwill remained at zero.
The absence of goodwill means impairment risk is not a concern, and PP&E at under 10% of total assets is consistent with the outsourced manufacturing model implied by low CapEx intensity. The near doubling of total assets over the period appears to reflect cash accumulation and intangible or receivable growth rather than capital-intensive expansion, so the quality of those non-PP&E assets warrants further investigation.
Deferred Revenue Collapse Signals Lumpy Income
According to reported figures, ALNY's deferred revenue fell from $72.0M in 2024Q3 to just $11.7M in 2026Q3, a decline that may indicate fewer upfront partner payments being carried forward on the balance sheet.
Deferred revenue dropping to low single-digit millions suggests that the headline revenue growth is not being supported by a growing backlog of prepaid obligations, which reduces the visibility that such balances typically provide. This pattern is consistent with the earlier finding that milestone and collaboration income drive much of the quarterly variability, and investors should not extrapolate current revenue levels without adjusting for that lumpiness.